IL6 and cancer: It seems to be an article of faith today among investigators and physicians that treating patients with COVID-19 or cancer patients with anti-IL-6 mAb, which “neutralize” IL-6 bioactivity in cell culture, should have similar neutralizing effects in vivo [74].